Navigation Links
50 percent of recent onset RA patients become free of signs and symptoms within 36 weeks
Date:6/11/2008

Paris, France, Wednesday June 11th 2008: At least 50% of recent onset rheumatoid arthritis patients achieve remission (a state free of signs and symptoms) within 36 weeks when following a systematic approach of step-up DMARD treatment in combination with tight control, according to results of a study presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. Results of this study indicate that achieving remission is not only possible during clinical trials but can be a realistic goal of standard clinical care.

Of 169 early RA patients, remission (defined as DAS28<2.6) was achieved in 15.5% at week 8 (23/148), 22.2% at week 12 (24/108), 30.7% at week 20 (23/75), 38.8% at week 24 (33/85), 52.1% at week 36 (38/73) and 51% at week 48-52 (26/51).

The researchers achieved these results through implementation of a tightly regulated DMARD treatment scheme, as follows:

  • Methotrexate 15mg/week was initiated following diagnosis

  • If remission was not achieved at week 8, the dose was increased to 25mg/week

  • If not achieved at week 12, sulfasalazine was added (2grams/day)

  • If not achieved at week 20, the dose was increased to 3grams/day

  • If not achieved at week 24 adalimumab was added to methotrexate

  • Every 3 months thereafter, therapy could be adjusted based on DAS28, also using other TNF-blockers. Patients were allowed to take NSAIDs, and prednisolone ≤10mg/day and intra-articular corticosteroid injections could be administered

Dr. H. Kuper and Prof M. van de Laar of Medisch Spectrum Twente & University Twente, the Netherlands, who led the study, said; "In many large clinical trials, remission can be considered a realistic goal. We set out to determine whether all patients presenting in daily clinical practice can reasonably expect to achieve a state free of signs and symptoms, if a strict treatment schedule was followed. Our results show that remission is indeed achievable in as many as half of clinical practice patients following this schedule, which could indicate that remission is a realistic treatment goal of daily clinical practice."

As part of the Dutch Rheumatoid Arthritis Monitoring Registry (DREAM), investigators performed a prospective descriptive study of a cohort of recent onset rheumatoid arthritis DMARD-nave, patients in daily clinical practice, between January 2006 and January 2008. 190 consecutive patients with recently diagnosed RA under the care of the rheumatology clinics of three hospitals in the Netherlands were included. Results were taken from the first 169 patients with DAS28>3.2 at inclusion.

At baseline, patient characteristics between the hospitals were comparable average patient age was 57.3 years (13.7), 63.9% were female, 52.7% of which were rheumatoid factor positive, with an average disease duration of 16 weeks (1-52), ESR 33.2 (20.5), CRP 23.5 (26.4), DAS28 5.1 (1.1), HAQ 1.3 (0.6).


'/>"/>

Contact: Camilla Dormer / Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-077-892-70392
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
2. 13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
3. Ninety Percent of Polled Pain Care Professionals Express Fear of Regulation
4. Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation
5. Less than 3 percent of UK 11-year-olds take enough exercise
6. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
7. Hospitals See Infection Rates More Than Halved, Patient Stays Shortened by 27 Percent in New Study Announced by I-Flow
8. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
9. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
10. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
11. Sixty Percent of Americans Cannot Name Top Killers of Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: